Mangoceuticals

Mangoceuticals EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Mangoceuticals (MGRX) as of Oct 22, 2026 is -0.90. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -1.36 — a change of -33.66% (higher).

EV/OCF

-0.90

YoY

-33.66%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Mangoceuticals is 2025 -0.90 . EV/OCF (Enterprise Value to Operating Cash Flow) of Mangoceuticals was 2024 -1.36 . It decreases by -33.66% higher compared to the previous year.

The Mangoceuticals EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2021
-369.13 USD
Jan 1, 2022
-4.55 USD
Jan 1, 2023
-0.83 USD
Jan 1, 2024
-1.36 USD
Jan 1, 2025
-0.90 USD
The Mangoceuticals EV/OCF history
YEAREV/OCFYoY
-0.90-33.66%
-1.36+62.75%
-0.83-81.64%
-4.55-98.77%
-369.13—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mangoceuticals Stock analysis

What does Mangoceuticals do? Mangoceuticals, Inc. generates revenue through its telemedicine platform by developing, marketing, and selling men’s wellness products, primarily the Mango ED product. The Mango ED product, available in two formulations with Tadalafil (10mg or 20mg) combined with Oxytocin (100IU) and L-Arginine (50mg), is marketed via the company's telehealth service. Customers access licensed healthcare professionals through MangoRX.com, receive prescriptions, and purchase the product through a partnered pharmacy for online fulfillment. The company targets men seeking ED solutions through a digital health platform, leveraging telemedicine to connect users with healthcare providers and facilitate medication distribution. The firm’s primary product, Mango ED, is sold through its telehealth platform, which integrates consultations with licensed professionals and pharmacy services. Consumers use the MangoRX.com portal to engage with healthcare providers, obtain prescriptions, and receive the Mango ED product via online pharmacy delivery. The company focuses on the men’s wellness market, specifically addressing erectile dysfunction with its branded medication, and monetizes through the sale of these products and associated telehealth services. Mangoceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mangoceuticals stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Mangoceuticals is -0.90 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Mangoceuticals changed from -1.36 to -0.90, representing a -33.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Mangoceuticals since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Mangoceuticals with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Mangoceuticals

All Key Metrics — Mangoceuticals